SCHEMBL1235947

SCHEMBL1235947

CC(CN)CCNC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
EPHX1 P07099 1/20 0.39
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.36
ANPEP P15144 2/20 0.36
ERAP2 Q6P179 2/20 0.36
RAD52 P43351 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
CXCR4 P61073 2/20 0.35
CXCL12 P48061 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11052652 0.82 KDM4E (0.41) KDM4EEPHX1ALDH1A1RAD52SMN1; SMN2
SCHEMBL11057051 0.81 CYP1A2 (0.40) KDM4EEPHX1ALDH1A1RAD52SMN1; SMN2
SCHEMBL28834995 0.80 KDM4E (0.52) KDM4EEPHX1TP53ANPEPERAP2
SCHEMBL10895092 0.80 KDM4E (0.42) KDM4EALDH1A1ANPEPERAP2RAD52
SCHEMBL7777018 0.79 ALDH1A1 (0.52) KDM4EEPHX1ALDH1A1ANPEPERAP2
SCHEMBL3679901 0.79 ALDH1A1 (0.52) KDM4EEPHX1ALDH1A1ANPEPERAP2
SCHEMBL20635257 0.79 KDM4E (0.42) KDM4EEPHX1ALDH1A1ANPEPERAP2
SCHEMBL11054753 0.78 EPHX1 (0.39) KDM4EEPHX1CXCR4CXCL12CYP1A2
SCHEMBL15108080 0.78 KDM4E (0.48) KDM4EEPHX1TP53ANPEPERAP2
SCHEMBL7776906 0.77 ALDH1A1 (0.53) KDM4EEPHX1ALDH1A1RAD52SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2464373-A1 METHOD FOR MODULATING THE PHARMACODYNAMIC EFFECT OF ORALLY ADMINISTERED GUANYLATE CYCLASE RECEPTOR AGONISTS Ironwood Pharmaceuticals, Inc. (US) 2012-06-20 EP claimed
WO-2011020054-A1 METHOD FOR MODULATING THE PHARMACODYNAMIC EFFECT OF ORALLY ADMINISTERED GUANYLATE CYCLASE RECEPTOR AGONISTS Ironwood Pharmaceuticals Inc. (US) 2011-02-17 WO claimed